Our study suggests that, despite well-described risk factors for poor outcome of COVID-19 infection are highly represented in our cohort, COVID-19 liver transplant patients show a clinical course not necessarily more severe to that observed in non-liver transplant patients affected by COVID-19.25–27 Publications pooling patients with different organ transplanted reported worse outcomes (in-hospital case fatality rate 24%–27%).11 13 Another publication merging surveys from European and American centres with a smaller sample than our prospective study reported 9 deaths among 39 liver transplant patients.28 Like others, we find that male patients are more prone to develop ARDS29 and have a more severe outcome.25 Although highly frequent in our cohort, CV and metabolic comorbidities were not over-represented in patients with poor outcomes.25 26 History of previous or active cancer, such as being transplanted for HCC or having cancer at the moment of the COVID-19 diagnosis, was associated with a poor outcome. This is in agreement with a national Chinese report on over 2000 confirmed COVID-19 cases with a history of cancer, showing them having higher risk to contract COVID-19 and poorer outcome than individuals without cancer.30 31